Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir

J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):e30. doi: 10.1097/QAI.0000000000002861.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Dideoxynucleosides / therapeutic use
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Lamivudine / therapeutic use
  • Oxazines / therapeutic use
  • Piperazines
  • Pyridones / therapeutic use

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Lamivudine
  • dolutegravir
  • abacavir